Blockade of the renin-angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver

Clinical and Experimental Metastasis

Volumn 31, Issue 4, 2014, Pages 395-405

  Koh, Shir Lin ^a   Ager, E I ^a   Costa, P L N ^a   Malcontenti Wilson, C ^a   Muralidharan, V ^a   Christophi, C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Colorectal cancer liver metastases; Liver regeneration; Mouse model; Partial hepatectomy; Tumor growth and stimulation

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIVER REGENERATION; LIVER WEIGHT; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PARTIAL HEPATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CBA MOUSE; COLORECTAL NEOPLASMS; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENETICS; LIVER NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SECONDARY; TUMOR CELL CULTURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; APOPTOSIS; CAPTOPRIL; CELL PROLIFERATION; COLORECTAL NEOPLASMS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LIVER REGENERATION; MALE; MICE; MICE, INBRED CBA; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84898602167     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9635-8     Document Type: Article

References (40)

1. Saenz NC, Cady B, McDermott WV Jr, Steele GD Jr (1989) Experience with colorectal carcinoma metastatic to the liver. Surg Clin North Am 69(2):361-370 (Pubitemid 19092641)
2. Pestana C, Reitemeier RJ, Moertel CG, Judd ES, Dockerty MB (1964) The natural history of carcinoma of the colon and rectum. Am J Surg 108:826-829
3. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. (1997) Liver resection for colorectal metastases. J Clin Oncol 15(3):938-946 (Pubitemid 27106275)
4. Ferlay J, Bray F, Pisani P,, et al. (eds.) (2004) GLOBOCAN 2002: Cancer incidence, mortality and prevalence world-wide. IARC CancerBase, No. 5 Version 2.0. Lyon, France: International Agency for Research on Cancer. Available from: http://www-dep.iarc.fr/. Accessed 18 Nov 2008
5. Fong Y, Bentrem DJ (2006) CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 243(1):8-9 (Pubitemid 43054047)
6. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065-2072 (Pubitemid 46622116)
7. Widakowich C, De Castro G Jr, De Azambuja E, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12(12):1443-1455
8. Koh SL, Ager EI, Christophi C (2010) Liver regeneration and tumour stimulation: implications of the renin-angiotensin system. Liver Int 30(10):1414-1426
9. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, et al. (2003) Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2(11):1139-1147
10. Attoub S, Gaben AM, Al-Salam S, Al-Sultan MA, John A, Nicholls MG, et al. (2008) Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci 1138:65-72
11. Greco AJMR, Fokin A Jr, Baber SR, Kadowitz PJ (2006) Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I. Can J Physiol Pharmacol 84(11):1163-1175 (Pubitemid 46465929)
12. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C (2010) Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 10(1):134
13. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C (2007) Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 22(4):577-584 (Pubitemid 46434989)
14. Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M (2002) Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62(15):4176-4179 (Pubitemid 34830392)
15. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294(2):441-447 (Pubitemid 34694114)
16. Noguchi R, Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, et al. (2003) Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9(16 Pt 1):6038-6045 (Pubitemid 38018091)
17. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98(3):671-679 (Pubitemid 26349171)
18. Kedika R, Patel M, Pena Sahdala HN, Mahgoub A, Cipher D, Siddiqui AA (2011) Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol 45(2):e12-e16
19. Yayama K, Miyagi R, Sugiyama K, Sugaya T, Fukamizu A, Okamoto H (2008) Angiotensin II regulates liver regeneration via type 1 receptor following partial hepatectomy in mice. Biol Pharm Bull 31(7):1356-1361 (Pubitemid 351930646)
20. Yayama K, Sugiyama K, Miyagi R, Okamoto H (2007) Angiotensin-converting enzyme inhibitor enhances liver regeneration following partial hepatectomy: involvement of bradykinin B2 and angiotensin AT1 receptors. Biol Pharm Bull 30(3):591-594 (Pubitemid 46355936)
21. Ramalho FS, Ramalho LN, Castro ESJO, Zucoloto S, Correa FM (2001) Angiotensin-converting enzyme inhibition by lisinopril enhances liver regeneration in rats. Braz J Med Biol Res 34(1):125-127 (Pubitemid 32128216)
22. Ramalho FS, Ramalho LN, Castro-e-Silva Junior O, Zucoloto S, Correa FM (2002) Effect of angiotensin-converting enzyme inhibitors on liver regeneration in rats. Hepatogastroenterology 49(47):1347-1351
23. Ager EI, Neo J, Christophi C (2008) The renin-angiotensin system and malignancy. Carcinogenesis 29(9):1675-1684
24. Ohta T, Amaya K, Yi S, Kitagawa H, Kayahara M, Ninomiya I, et al. (2003) Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues. Int J Oncol 23(3):593-598
25. Sato T, El-Assal ON, Ono T, Yamanoi A, Dhar DK, Nagasue N (2001) Sinusoidal endothelial cell proliferation and expression of angiopoietin/Tie family in regenerating rat liver. J Hepatol 34(5):690-698 (Pubitemid 32488784)
26. Ager EI, Chong WW, Wen SW, Christophi C (2010) Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases. Cancer Cell Int 10:19
27. Balabaud C, Bioulac-Sage P, Desmouliere A (2004) The role of hepatic stellate cells in liver regeneration. J Hepatol 40(6):1023-1026 (Pubitemid 38670138)
28. Ramalho FS, Alfany-Fernandez I, Casillas-Ramirez A, Massip-Salcedo M, Serafin A, Rimola A, et al. (2008) Are Angiotensin II receptor antagonists useful strategies in steatotic and non-steatotic livers in conditions of partial hepatectomy under ischemia-reperfusion? J Pharmacol Exp Ther 329(1):130-140
29. Ramalho LN, Zucoloto S, Ramalho FS, Castro-e-Silva O Jr, Correa FM (2003) Effect of antihypertensive agents on stellate cells during liver regeneration in rats. Arq Gastroenterol 40(1):40-44 (Pubitemid 37463226)
30. Harun N, Costa P, Christophi C (2014) Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met. Clin Exp Metastasis 31(1):1-14
31. Stahlberg AKM, Pfaffl M (2004) Comparison of reverse transcriptases in gene expression analysis. Clin Chem 50(9):1678-1680 (Pubitemid 39121243)
32. Pfaffl M (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45
33. Koh SL, Ager E, Malcontenti-Wilson C, Muralidharan V, Christophi C (2013) Blockade of the renin-angiotensin system improves the early stages of liver regeneration and liver function. J Surg Res 179(1):66-71
34. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277-285 (Pubitemid 28015876)
35. de Groot-Besseling RR, Ruers TJ, van Kraats AA, Poelen GJ, Ruiter DJ, de Waal RM, et al. (2004) Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer 112(2):329-334 [Research Support, Non-U.S. Gov't] (Pubitemid 39244374)
36. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6(5):507-516 (Pubitemid 39469986)
37. Heffelfinger SC (2007) The renin angiotensin system in the regulation of angiogenesis. Curr Pharm Des 13(12):1215-1229 (Pubitemid 46739330)
38. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, et al. (1997) The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proceedings of the National Academy of Sciences of the United States of America. 94(20):10868-10872 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.] (Pubitemid 27430827)
39. Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, et al. (2005) Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats. Anticancer Res 25(5):3335-3340 (Pubitemid 41105209)
40. Barugel ME, Vargas C, Krygier Waltier G (2009) Metastatic colorectal cancer: recent advances in its clinical management. Expert Rev Anticancer Ther 9(12):1829-1847